高级检索
当前位置: 首页 > 详情页

Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC)

文献详情

资源类型:
机构: [1]Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China; [2]State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [3]Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China; [4]Sun Yat Sen Univ, Dept Oncol, Affiliated Hosp 5, Zhuhai 519000, Peoples R China
出处:
ISSN:

关键词: Small-cell lung cancer Low-density lipoprotein Low-density lipoprotein receptor Prognosis

摘要:
Background: Patients with small-cell lung cancer (SCLC) patients demonstrate varied survival outcomes. Previous studies have reported that lipoproteins are associated with prognosis in various cancers; however, the role of low-density lipoprotein (LDL) and low-density lipoprotein-cholesterol (LDLR) in patients with SCLC has not been studied. Methods: In this study, the impact of LDL and LDLR on the prognosis of SCLC patients was evaluated. A total of 601 patients with SCLC were retrospectively evaluated, in which 198 patients had adequate tissues for immunohistochemistry, and serum LDL and LDLR expression levels at baseline were tested. X-tile tool, and univariate and multivariate Cox analysis were used to assess the association between LDL, LDLR and overall survival (OS). Results: Univariate analysis demonstrated that a lower LDL level was significantly associated with superior OS (P = 0.037). Similarly, LDLR also significantly predicted OS (P = 0.003). Multivariate Cox analyses confirmed that lower LDL and LDLR expression was independent prognostic factors associated with longer OS (P = 0.019 and P = 0.027, respectively). Conclusions: This study showed that both LDL and LDLR are prognostic indexes for survival in patients with SCLC. Patients with high LDL or LDLR expression level may benefit from treatment that modulates lipoprotein combined with platinum-based chemotherapy.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2023]版:
大类 | 2 区 医学
小类 | 3 区 肿瘤学
第一作者:
第一作者机构: [1]Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China; [2]State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [3]Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China;
通讯作者:
通讯机构: [1]Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China; [2]State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [3]Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China;
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43389 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号